Marc Beer co-founded a company specializing in the development of products related to female maladies and he is currently serving as the company’s Chief Executive Officer. But in order to develop products that are of importance to women who are suffering from maladies, there must be great monetary resources to put into research and development programs. To this end, Marc Beer raised $42 million from three healthcare investors, the New York-based Perspective Advisors, the Missouri-based Ascension Ventures, and the Longwood Fund. The raised funds will be allocated to developing and testing four new therapeutic and diagnostic products as well as to developing and testing a newer version of Leva, Renovia’s first product.
Renovia Inc. is the Boston-based company that Marc Beer co-founded for the express purpose of helping women better deal with their common female malady known as pelvic floor disorders. Urinary incontinence is one of the most common pelvic floor disorders, which by some accounts, affects 250 million women across the globe. Renovia’s attempt to develop products to help women deal with pelvic floor disorders has been met with some success. In April of this year, Renovia was successful in securing the FDA’s approval for its first product, Leva. Renovia’s purpose for existence is to provide a means to better diagnose and treat pelvic floor disorders, as well as to improve the quality of life of the millions of women who are suffering from the symptoms of the various types of pelvic floor disorders.
Marc Beer has extensive experience in developing and commercializing biotechnology, pharmaceuticals, devices, and diagnostics to the tune of over 25 years. Marc Beer attended the Miami University in Ohio and graduated therefrom with a degree. In addition to founding Renovia, Marc Beer also founded ViaCell, Good Start Genetics, Inc., and Minerva Neurosciences Inc. In April of 2000, Marc Beer founded ViaCell and served as the company’s Chief Executive Officer. ViaCell is a biotech company that specializes in collecting, preserving, and developing umbilical cord blood stem cells. In 2005, ViaCell went public as a result of Marc’s leadership. Marc Beer also founded Good Start Genetics, Inc. and served as the company’s chairman of the board of directors and chairman of the compensation committee. Moreover, Marc Beer founded Minerva Neurosciences Inc. and served as the company’s chairman of the board, chairman of the compensation committee, and a member of the audit committee. Learn more: https://www.fiercebiotech.com/medtech/renovia-raises-42m-to-fund-digital-health-solutions-for-pelvic-floor-strengthening